Search

Displaying results 5631 - 5640 of 7058 in total
  1. Drug

    AOD9604

    go.drugbank.com/drugs/DB06388
    Experimental

    AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.

  2. Drug

    Remacemide

    go.drugbank.com/drugs/DB06458
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  4. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Liatermin

    go.drugbank.com/drugs/DB06489
    Investigational

  6. Drug

    Sufugolix

    go.drugbank.com/drugs/DB06494
    Experimental

  7. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  8. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

  9. Drug

    TAS-106

    go.drugbank.com/drugs/DB06656
    Investigational

    TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

  10. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. … During a search for antibiotic compounds produced by fungi in 1971, Akira Endo at Sankyo Co. (Japan) discovered a class of compounds that appeared to lower plasma cholesterol levels.